Management of venous thromboembolism in patients with cancer (Q37903957)

25 August 2017

1 reference

title

Management of venous thromboembolism in patients with cancer. (English)

1 reference

25 August 2017

main subject

venous thromboembolism

1 reference

G Agnelli

1

1 reference

25 August 2017

M Verso

series ordinal

2

1 reference

25 August 2017

publication date

1 July 2011

1 reference

Journal of Thrombosis and Haemostasis

25 August 2017

published in

1 reference

25 August 2017

volume

9 Suppl 1

1 reference

25 August 2017

page(s)

316-324

1 reference

Impact of venous thromboembolism and anticoagulation on cancer and cancer survival

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Incidence of venous thromboembolism and the impact on survival in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

The incidence of venous thromboembolism among patients with primary lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Gr

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

The impact of venous thromboembolism on risk of death or hemorrhage in older cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Venous Thromboembolism Associated With Long-Term Use of Central Venous Catheters in Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Lessons from French National Guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Thromboembolism in hospitalized neutropenic cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Development and validation of a predictive model for chemotherapy-associated thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Prediction of venous thromboembolism in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

D-dimer before chemotherapy might predict venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Elevated D-dimers are also a marker of underlying malignancy and increased mortality in the absence of venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Low-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Minidose warfarin is associated with a high incidence of International Normalized Ratio elevation during chemotherapy with FOLFOX regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Elevated International Normalized Ratio associated with concurrent use of sorafenib and warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Elevated international normalized ratio associated with concomitant warfarin and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Metastatic cancer. A relative contraindication to vena cava filter placement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Thromboembolic complications in patients with advanced cancer: anticoagulation versus Greenfield filter placement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Treatment of deep vein thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors. Anticoagulants or inferior vena cava filter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Unsuspected pulmonary embolism: prospective detection on routine helical CT scans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Prevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Incidental pulmonary emboli in oncology patients: prevalence, CT evaluation, and natural history

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

21 January 2018

Acute pulmonary embolism

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Acute and long term management of pulmonary embolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Incidence and risk of thromboembolism during treatment of high-grade gliomas: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Bevacizumab antiangiogenic therapy for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Therapy of venous thromboembolism in patients with brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Risk of intracranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Incidence and treatment of peripheral venous thrombosis in patients with glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Low molecular weight heparin for deep vein thrombosis in glioma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Management of venous thromboembolism in patients with primary and metastatic brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Prognosis of Cancers Associated with Venous Thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Ovarian cancer and venous thromboembolic risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: a post-hoc analysis of the PROLONG study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2011.04346.X

10.1111/J.1538-7836.2011.04346.X

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference